Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Receives Consensus Rating of “Hold” from Analysts

Shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) have received an average rating of “Hold” from the six analysts that are covering the firm, MarketBeat Ratings reports. Four research analysts have rated the stock with a hold recommendation and two have issued a buy recommendation on the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $17.25.

Several brokerages recently issued reports on AUPH. Jefferies Financial Group upgraded shares of Aurinia Pharmaceuticals from a “hold” rating to a “buy” rating and lifted their price target for the stock from $10.00 to $21.00 in a research note on Friday, November 7th. Bloom Burton cut shares of Aurinia Pharmaceuticals from a “moderate buy” rating to a “hold” rating in a research note on Wednesday, November 5th. Weiss Ratings reissued a “hold (c)” rating on shares of Aurinia Pharmaceuticals in a research report on Wednesday, January 21st. Royal Bank Of Canada reaffirmed a “sector perform” rating and set a $15.00 price objective (up from $9.00) on shares of Aurinia Pharmaceuticals in a report on Wednesday, November 5th. Finally, Leerink Partners cut Aurinia Pharmaceuticals from an “outperform” rating to a “market perform” rating and increased their target price for the stock from $15.00 to $16.00 in a report on Wednesday, December 3rd.

Aurinia Pharmaceuticals Stock Performance

NASDAQ:AUPH opened at $14.23 on Friday. The company has a current ratio of 5.76, a quick ratio of 5.17 and a debt-to-equity ratio of 0.15. Aurinia Pharmaceuticals has a 1 year low of $6.55 and a 1 year high of $16.54. The firm’s fifty day simple moving average is $15.25 and its 200 day simple moving average is $13.68. The firm has a market capitalization of $1.88 billion, a PE ratio of 25.41 and a beta of 1.50.

Institutional Trading of Aurinia Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. BOK Financial Private Wealth Inc. acquired a new position in shares of Aurinia Pharmaceuticals during the fourth quarter worth approximately $32,000. Northwestern Mutual Wealth Management Co. acquired a new position in Aurinia Pharmaceuticals during the 3rd quarter worth $48,000. State of Alaska Department of Revenue bought a new position in Aurinia Pharmaceuticals in the 3rd quarter valued at $91,000. Vanguard Personalized Indexing Management LLC acquired a new stake in shares of Aurinia Pharmaceuticals in the 2nd quarter valued at $92,000. Finally, Bailard Inc. acquired a new stake in shares of Aurinia Pharmaceuticals in the 2nd quarter valued at $99,000. 36.83% of the stock is currently owned by institutional investors and hedge funds.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases. The company’s proprietary molecule, voclosporin, is designed to selectively inhibit calcineurin and reduce inflammation associated with autoimmune responses. Aurinia operates research and development facilities in Canada and the United States, leveraging collaborations with academic institutions and contract research organizations to advance its clinical pipeline.

The company’s lead product, voclosporin (marketed as LUPKYNIS), received approval from the U.S.